Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$122.66 USD

122.66
2,716,497

-0.16 (-0.13%)

Updated Jul 12, 2024 01:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More

by Zacks Equity Research

Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.

Moderna (MRNA) Stock Moves -0.53%: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $134, moving -0.53% from the previous trading session.

Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study

by Zacks Equity Research

Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine.

Pfizer (PFE) Posts Positive Data on Bivalent BA.4/5 COVID Jab

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech's Omicron BA.4/BA.5-adapted bivalent COVID vaccine exhibits substantial antibody response above pre-booster levels in adults after seven days of dose administration.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK

by Zacks Equity Research

Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.

Sundeep Ganoria headshot

FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids

by Sundeep Ganoria

Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.

Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab

by Zacks Equity Research

Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab

by Kinjel Shah

FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.

Moderna (MRNA) Soars 8.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Albireo Pharma (ALBO) Soars 14.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Novavax's (NVAX) COVID-19 Booster Recommended in Switzerland

by Zacks Equity Research

The Federal Office of Public Health in Switzerland recommends Novavax's (NVAX) COVID-19 vaccine, Nuvaxovid, as a booster for both heterologous and homologous use in adults aged 18 years and older.

Here's Why You Should Invest in Vertex (VRTX) Stock Now

by Zacks Equity Research

Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.

Moderna (MRNA) Stock Moves -0.04%: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $125.62, marking a -0.04% move from the previous day.

Why Novavax's (NVAX) COVID Vaccine Struggles for Market Share?

by Zacks Equity Research

Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

by Zacks Equity Research

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

by Zacks Equity Research

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $122.15 in the latest trading session, marking a -0.07% move from the prior day.

Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19 booster vaccine in kids. The vaccine is already authorized for use in adolescents and adults.

Why Novavax (NVAX) Stock Was Down 13% on Thursday

by Zacks Equity Research

Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $124.32, marking a -1.15% move from the previous day.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

by Zacks Equity Research

Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.

Kinjel Shah headshot

Vaccine Stocks Down After Biden Says Pandemic is Over

by Kinjel Shah

BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.

Company News for Sep 20, 2022

by Zacks Equity Research

Companies in The News Are: WIX,COIN,TBPH,GSK,MRNA

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $137.74, marking a +1.38% move from the previous day.

Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine

by Zacks Equity Research

Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.